Potent in vitro and in vivo activity of sorafenib in multiple myeloma: Induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization

British Journal of Haematology

Volumn 161, Issue 1, 2013, Pages 104-116

  Udi, Josefina ^a   Schüler, Julia ^a,b   Wider, Dagmar ^a   Ihorst, Gabriele ^a   Catusse, Julie ^a   Waldschmidt, Johannes ^a   Schnerch, Dominik ^a   Follo, Marie ^a   Wäsch, Ralph ^a   Engelhardt, Monika ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Antimyeloma agents; Chemotaxis; Microenvironment; Multiple myeloma; NSG

Indexed keywords

ACTIN; BORTEZOMIB; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CYTOCHROME C; EPIGALLOCATECHIN GALLATE; GREEN FLUORESCENT PROTEIN; HISTONE H2B; INTERLEUKIN 2 RECEPTOR GAMMA; LENALIDOMIDE; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RANTES; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; SYNDECAN 1; THALIDOMIDE;

ACTIN POLYMERIZATION; ADULT; AGED; AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN L363; CELL STRAIN RPMI8226; CHEMOTAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLYMERIZATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FEMALE; FOOT DISEASE; HAND DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEG CRAMP; MALE; MORPHOLOGY; MOUSE; MOUTH INFLAMMATION; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PYREXIA IDIOPATHICA; SCID MOUSE; SKIN MANIFESTATION; STROMA CELL; TREATMENT RESPONSE;

ACTINS; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CHEMOKINE CXCL12; CHEMOTAXIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; POLYMERIZATION; PYRAZINES; SYNDECAN-1; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875050694     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12226     Document Type: Article

References (39)

1. Alexandrescu, D.T., McClure, R., Farzanmehr, H. & Dasanu, C.A. (2008) Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. Journal of Clinical Oncology, 26, 4047-4048.
2. Badr, G., Lefevre, E.A. & Mohany, M. (2011) Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis. PLoS ONE, 6, e23741.
3. Beck, B., Driessens, G., Goossens, S., Youssef, K.K., Kuchnio, A., Caauwe, A., Sotiropoulou, P.A., Loges, S., Lapouge, G., Candi, A., Mascre, G., Drogat, B., Dekoninck, S., Haigh, J.J., Carmeliet, P. & Blanpain, C. (2011) A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature, 478, 399-403.
4. Benitah, S.A. (2011) Tumour biology: skin-cancer stem cells outwitted. Nature, 478, 329-330.
5. Bossy-Wetzel, E., Newmeyer, D.D. & Green, D.R. (1998) Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO Journal, 17, 37-49.
6. Burger, M., Hartmann, T., Krome, M., Rawluk, J., Tamamura, H., Fujii, N., Kipps, T.J. & Burger, J.A. (2005) Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood, 106, 1824-1830.
7. Calimeri, T., Battista, E., Conforti, F., Neri, P., Di Martino, M.T., Rossi, M., Foresta, U., Piro, E., Ferrara, F., Amorosi, A., Bahlis, N., Anderson, K.C., Munshi, N., Tagliaferri, P., Causa, F. & Tassone, P. (2011) A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia, 25, 707-711.
8. Chauhan, D., Singh, A., Brahmandam, M., Podar, K., Hideshima, T., Richardson, P., Munshi, N., Palladino, M.A. & Anderson, K.C. (2008) Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood, 111, 1654-1664.
9. Chou, T.C. (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research, 70, 440-446.
10. DeWeerdt, S. (2011) Animal models: towards a myeloma mouse. Nature, 480, S38-39.
11. Edwards, C.M., Lwin, S.T., Fowler, J.A., Oyajobi, B.O., Zhuang, J., Bates, A.L. & Mundy, G.R. (2009) Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. American Journal of Hematology, 84, 268-272.
12. Fan, F., Schimming, A., Jaeger, D. & Podar, K. (2012) Targeting the tumor microenvironment: focus on angiogenesis. Journal of oncology, 2012, 281261.
13. Fuchida, S.I., Shimazaki, C., Hirai, H., Akamatsu, S., Yamada, N., Uchida, R., Okano, A., Okamoto, M., Inaba, T. & Taniwaki, M. (2008) The effects of thalidomide on chemotactic migration of multiple myeloma cell lines. International journal of laboratory hematology, 30, 220-229.
14. Goldstein, J.C., Waterhouse, N.J., Juin, P., Evan, G.I. & Green, D.R. (2000) The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nature Cell Biology, 2, 156-162.
15. Goldstein, J.C., Munoz-Pinedo, C., Ricci, J.E., Adams, S.R., Kelekar, A., Schuler, M., Tsien, R.Y. & Green, D.R. (2005) Cytochrome c is released in a single step during apoptosis. Cell Death and Differentiation, 12, 453-462.
16. Hideshima, T. & Anderson, K.C. (2011) Novel therapies in MM: from the aspect of preclinical studies. International Journal of Hematology, 94, 344-354.
17. Hideshima, T., Chauhan, D., Podar, K., Schlossman, R.L., Richardson, P. & Anderson, K.C. (2001a) Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Seminars in Oncology, 28, 607-612.
18. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001b) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 3071-3076.
19. Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N.C., Richardson, P.G., Carrasco, R.D. & Anderson, K.C. (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood, 114, 1046-1052.
20. Kyle, R.A. & Rajkumar, S.V. (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia, 23, 3-9.
21. LeBlanc, R., Catley, L.P., Hideshima, T., Lentzsch, S., Mitsiades, C.S., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C.S., Adams, J., Gupta, D., Richardson, P.G., Munshi, N.C. & Anderson, K.C. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research, 62, 4996-5000.
22. Menu, E., Braet, F., Timmers, M., Van Riet, I., Van Camp, B. & Vanderkerken, K. (2002) The F-actin content of multiple myeloma cells as a measure of their migration. Annals of the New York Academy of Sciences, 973, 124-136.
23. Miller, A.A., Murry, D.J., Owzar, K., Hollis, D.R., Kennedy, E.B., Abou-Alfa, G., Desai, A., Hwang, J., Villalona-Calero, M.A., Dees, E.C., Lewis, L.D., Fakih, M.G., Edelman, M.J., Millard, F., Frank, R.C., Hohl, R.J. & Ratain, M.J. (2009) Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. Journal of Clinical Oncology, 27, 1800-1805.
24. Moller, C., Stromberg, T., Juremalm, M., Nilsson, K. & Nilsson, G. (2003) Expression and function of chemokine receptors in human multiple myeloma. Leukemia, 17, 203-210.
25. Ngo, H.T., Azab, A.K., Farag, M., Jia, X., Melhem, M.M., Runnels, J., Roccaro, A.M., Azab, F., Sacco, A., Leleu, X., Anderson, K.C. & Ghobrial, I.M. (2009) Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clinical Cancer Research, 15, 6035-6041.
26. Ramakrishnan, V., Timm, M., Haug, J.L., Kimlinger, T.K., Wellik, L.E., Witzig, T.E., Rajkumar, S.V., Adjei, A.A. & Kumar, S. (2010) Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene, 29, 1190-1202.
27. Renz, A., Berdel, W.E., Kreuter, M., Belka, C., Schulze-Osthoff, K. & Los, M. (2001) Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood, 98, 1542-1548.
28. Rini, B.I. (2006) Sorafenib. Expert Opinion on Pharmacotherapy, 7, 453-461.
29. Schüler, J., Wider, D., Pfeifer, D., Udi, J., Fiebig, H.-H., Wäsch, R. & Engelhardt, M. (2009) Antitumor Activity of Novel Anti-MM Agents and Combinations, the Proteasome Inhibitor Bortezomib and Multikinase Inhibitor Sorafenib, Both Applied as Monotherapy and in Combination in NOD/SCID-IL2-Receptor-Gamma-chain -/- (NSG) Mice Using a Intratibial Tumor Dissemination approach. Blood, 114, Abstract 4912
30. Shammas, M.A., Neri, P., Koley, H., Batchu, R.B., Bertheau, R.C., Munshi, V., Prabhala, R., Fulciniti, M., Tai, Y.T., Treon, S.P., Goyal, R.K., Anderson, K.C. & Munshi, N.C. (2006) Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood, 108, 2804-2810.
31. Strumberg, D., Clark, J.W., Awada, A., Moore, M.J., Richly, H., Hendlisz, A., Hirte, H.W., Eder, J.P., Lenz, H.J. & Schwartz, B. (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist, 12, 426-437.
32. Tassone, P., Neri, P., Burger, R., Di Martino, M.T., Leone, E., Amodio, N. & Tagliaferri, P. (2012) Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma. Curr Cancer Drug Targets.
33. Teo, S.K., Stirling, D.I. & Zeldis, J.B. (2005) Thalidomide as a novel therapeutic agent: new uses for an old product. Drug discovery today, 10, 107-114.
34. Udi, J., Wider, D., Kleber, M., Ihorst, G., Muller, A., Wasch, R. & Engelhardt, M. (2011) Early and mature endothelial progenitors and VEGFR2 + -cells in multiple myeloma: association with disease characteristics and variation in different cell compartments. Leukemia Research, 35, 1265-1268.
35. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., Simantov, R. & Kelley, S. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews. Drug Discovery, 5, 835-844.
36. Yu, C., Friday, B.B., Lai, J.P., Yang, L., Sarkaria, J., Kay, N.E., Carter, C.A., Roberts, L.R., Kaufmann, S.H. & Adjei, A.A. (2006) Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Molecular Cancer Therapeutics, 5, 2378-2387.
37. Zhu, Y.X., Braggio, E., Shi, C.X., Bruins, L.A., Schmidt, J.E., Van Wier, S., Chang, X.B., Bjorklund, C.C., Fonseca, R., Bergsagel, P.L., Orlowski, R.Z. & Stewart, A.K. (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood, 118, 4771-4779.
38. Ziegler, U. & Groscurth, P. (2004) Morphological features of cell death. News in Physiological Sciences, 19, 124-128.
39. Zlei, M., Egert, S., Wider, D., Ihorst, G., Wasch, R. & Engelhardt, M. (2007) Characterization of in vitro growth of multiple myeloma cells. Experimental Hematology, 35, 1550-1561.